Source: New England Journal of Medicine. Unidade: FM
Subjects: DOENÇAS HEREDITÁRIAS, PLACEBOS (ADMINISTRAÇÃO E DOSAGEM), ANGIOEDEMA (GENÉTICA;TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIAVINA-BIANCHI, Pedro e MOTTA, Abílio e KALIL FILHO, Jorge. Clinical trials that compare a new drug to treat moderate-to-severe attacks of hereditary angioedema with placebo raise concerns. Cicardi et al. cite previous studies 1,2 and state, “Replacement therapy with intravenous C1 esterase-inhibitor concentrate reverses acute attacks.” [Carta]. New England Journal of Medicine. Boston: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 17 maio 2024. , 2011APA
Giavina-Bianchi, P., Motta, A., & Kalil Filho, J. (2011). Clinical trials that compare a new drug to treat moderate-to-severe attacks of hereditary angioedema with placebo raise concerns. Cicardi et al. cite previous studies 1,2 and state, “Replacement therapy with intravenous C1 esterase-inhibitor concentrate reverses acute attacks.” [Carta]. New England Journal of Medicine. Boston: Faculdade de Medicina, Universidade de São Paulo.NLM
Giavina-Bianchi P, Motta A, Kalil Filho J. Clinical trials that compare a new drug to treat moderate-to-severe attacks of hereditary angioedema with placebo raise concerns. Cicardi et al. cite previous studies 1,2 and state, “Replacement therapy with intravenous C1 esterase-inhibitor concentrate reverses acute attacks.” [Carta]. New England Journal of Medicine. 2011 ; 364( 1): 84-85.[citado 2024 maio 17 ]Vancouver
Giavina-Bianchi P, Motta A, Kalil Filho J. Clinical trials that compare a new drug to treat moderate-to-severe attacks of hereditary angioedema with placebo raise concerns. Cicardi et al. cite previous studies 1,2 and state, “Replacement therapy with intravenous C1 esterase-inhibitor concentrate reverses acute attacks.” [Carta]. New England Journal of Medicine. 2011 ; 364( 1): 84-85.[citado 2024 maio 17 ]